10Feb 2018

CONSEQUENCES OF DOPAMINERGIC AGONIST ASSOCIATED WITH BDNF TREATMENT ON BEHAVIORAL ALTERATIONS AND CYTOLOGICAL CHANGES IN AN EXPERIMENTAL MODEL OF PARKINSON DISEASE DUE TO MANGANESE EXPOSURE.

  • Laboratorio de neuromorfologia, FES iztacala, UNAM, av. De los barrios 1, tlalnepantla 54090, Mexico.
  • Departamento de fisiolog?a, biofisica y neurociencias, cinvestav-ipn, mexico av. Ipn 2508, cp 07360, Mexico.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Parkinson disease (PD) is characterized by dopaminergic (DA) neuronal loss and motor alterations; in this way, an effective therapy should protect and regenerate the DA neurons and striatal innervation. Brain-derived neurotrophic factor (BDNF) is a cell survival mediator and can improve neuronal death, and the activation of DA D3 receptors seems to protect the DA neurons. Thus, there is a synergistic relationship between BDNF and D3 receptors; which would be a neuroprotective therapy. PD animal models, although exhibit some of the features, no one mimics the alterations observed in the disease. PD-Manganese (Mn) inhalation model was used in this report since it is bilateral, non-invasive and progressive. The rats were exposed to Mn 1 hour 3 times a week, and the motor tests were conducted to measure the performance as well as the progressive damage at 3 and 6 months of exposure. Subsequently, the D3 agonist treatment (7-OH-DPAT) and BDNF gene transfection to DA neurons were co-administered, and then we evaluated its effect measuring the animals\\\' performance, and if the recovery was associated with DA neuronal and striatal dendritic spines preservation. The results showed that the animals presented PD-like motor alterations, and great DA neurons and striatal dendritic spines loss. The behavior recovery was associated with the DA neurons recuperation and with the number of dendritic spines of the striatal neurons. Thus, the BDNF overexpression in DA neurons related to the D3 receptors activation seems to be a promising approach for restoring motor alterations and DA neurons in PD.

  1. Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
  2. Alexander GE (2004) Biology of Parkinson\'s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in Clin Neurosci 6: 259-280.
  3. Alvarez-Maya I, Navarro-Quiroga I, Meraz-Rios MA, Aceves J, Martinez-Fong D (2001) In vivo gene transfer to dopamine neurons of rat substantia nigra via the high-affinity neurotensin receptor. Mol Med 7: 186-192.
  4. Avila-Costa MR, Montiel Flores E, Colin-Barenque L, Ordo?ez JL, Guti?rrez AL, Ni?o-Cabrera HG, Mussali-Galante P, Fortoul TI (2004) Nigrostriatal modifications after vanadium inhalation: an immunocytochemical and cytological approach. Neurochem Res 29: 1365-1369.
  5. Benraiss A, Chmielnicki E, Lerner K, Roh D, Goldman SA (2001) Adenoviral brain-derived neurotrophic factor induces both neostriatal and olfactory neuronal recruitment from endogenous progenitor cells in the adult forebrain. J Neurosci 21: 6718-6731.
  6. Betarbet R, Sherer TB, Greenamyre JT (2002) Animal models of Parkinson\'s disease. BioEssays 24: 308-318.
  7. Blochl A, Sirrenberg C (1996) Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. J Biol Chem 271: 21100-21107.
  8. Bukhatwa S, Iravani MM, Zeng BY, Cooper JD, Rose S, Jenner P (2009) An immunohistochemical and stereological analysis of PSI-induced nigral neuronal degeneration in the rat. J Neurochem 109: 52-59.
  9. Casarrubea M, Sorbera F, Crescimanno G (2006) Effects of 7-OH-DPAT and U 99194 on the behavioral response to hot plate test, in rats. Physiol Behav 89: 552-562.
  10. Chan H, Paur H, Vernon AC, Zabarsky V, Datla KP, Croucher MJ, Dexter DT (2010) Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson\'s Disease Parkinsons Dis 2010:190450.
  11. Chio CL, Lajiness ME, Huff RM (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45: 51-60.
  12. Collo G, Zanetti S, Missale C, Spano P (2008) Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation. Eur J Neurosci 28: 1231-1240.
  13. Connor B, Dragunow M (1998) The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Rev, 27: 1-39.
  14. Cummins G, Barker RA, (2012) What is the most promising treatment for Parkinson\'s disease: genes, cells, growth factors or none of the above? Regen Med, 7: 617-621.
  15. Day M, Wang Z, Ding J, An X, Ingham CA, Shering AF, Wokosin D, Ilijic E, et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9: 251-259.
  16. Diaz J, Ridray S, Mignon V, Griffon N, Schwartz JC, Sokoloff P (1997) Selective expression of dopamine D3 receptor mRNA in proliferative zones during embryonic development of the rat brain. J Neurosci 17: 4282-4292.
  17. Du F, Li R, Huang Y, Li X, Le W (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. Eur J Neurosci 22: 2422-2430.
  18. Emborg ME (2004) Evaluation of animal models of Parkinson\'s disease for neuroprotective strategies, J Neurosci Methods 139: 121-143.
  19. Fasano C, Bourque MJ, Lapointe G, Leo D, D. Thibault, M. Haber, Kortleven C, DesGroseillers L, et al. (2013) Dopamine facilitates dendritic spine formation by cultured striatal medium spiny neurons through both D1 and D2 dopamine receptors. Neuropharmacology 67: 432-443.
  20. Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG, Lu B (2010) Direct current stimulation promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. Neuron 66: 198-204.
  21. Goggi J, Pullar IA, Carney SL, Bradford HF (2002) Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res, 941: 34-42.
  22. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-Martinez V, Flores G, Navarro-Quiroga I, Trudeau LE, Aceves J, et al. (2006) Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther 14: 857-865.
  23. Griffon N, Pilon C, Sautel F, Schwartz JC, Sokoloff P (1997) Two intracellular signaling pathways for the dopamine D3 receptor: opposite and synergistic interactions with cyclic AMP. J Neurochem 68: 1-9.
  24. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411: 86-89.
  25. Hernandez-Baltazar D, Martinez-Fong D, Trudeau LE (2012) Optimizing NTS-polyplex as a tool for gene transfer to cultured dopamine neurons. PloS one 7: e51341.
  26. Hernandez-Chan NG, Bannon MJ, Orozco-Barrios CE, Escobedo L, Zamudio S, De la Cruz F, Gongora-Alfaro JL, Armendariz-Borunda J, et al. (2015) Neurotensin-polyplex-mediated brain-derived neurotrophic factor gene delivery into nigral dopamine neurons prevents nigrostriatal degeneration in a rat model of early Parkinson\'s disease. J Biomed Sci, 22: 59.
  27. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA (2000) Reduced BDNF mRNA expression in the Parkinson\'s disease substantia nigra. Exp Neurol 166: 127-135.
  28. Hyman C, Hofer M, Barde YA, Juhasz M, Yancopoulos GD, Squinto SP, Lindsay RM (1991) BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra, Nature, 350: 230-232.
  29. Im SH, Yu JH, Park ES, Lee JE, Kim HO, Park KI, Kim GW, Park CI, et al. (2010) Induction of striatal neurogenesis enhances functional recovery in an adult animal model of neonatal hypoxic-ischemic brain injury. Neuroscience 169: 259-268.
  30. Iravani MM, Kashefi K, Mander P, Rose S, Jenner P (2002) Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110: 49-58.
  31. Ma Y, Peng S, Dhawan V, Eidelberg D (2011) Dopamine cell transplantation in Parkinson\'s disease: challenge and perspective. Br Med Bull? 100: 173-189.
  32. Martin WR (2011) Fuming over Parkinson disease: are welders at risk?, Neurology 76: 1286-1287.
  33. Martinez-Fong D, Bannon MJ, Trudeau L-?, Gonzalez-Barrios JA, Arango-Rodriguez ML, Hernandez-Chan NG, Reyes-Corona D, Armend?riz-Borunda J, et al. (2012) NTS-Polyplex: A potential nanocarrier for neurotrophic therapy of Parkinson?s disease. Nanomedicine 8: 1052-1069.
  34. Merlo S, Canonico PL, Sortino MA (2011) Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype. Neuropharmacology 60: 892-900.
  35. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson\'s disease. Neurosci Lett, 270: 45-48.
  36. Naskar A, Manivasagam T, Chakraborty J, Singh R, Thomas B, Dhanasekaran M, Mohanakumar KP (2013) Melatonin synergizes with low doses of L-DOPA to improve dendritic spine density in the mouse striatum in experimental Parkinsonism. J Pineal Res 55: 304-301.
  37. Ouagazzal AM, Creese I (2000) Intra-accumbens infusion of D-3 receptor agonists reduces spontaneous and dopamine-induced locomotion. Pharmacol Biochem Behav 67: 637-645.
  38. Ord??ez-Librado JL, Anaya-Mart?nez V, Guti?rrez-Valdez AL, Col?n-Barenque L, Montiel-Flores E, Avila-Costa MR (2010a) Manganese inhalation as a Parkinson disease model. Parkinsons Dis 2011: 612989.
  39. Ordo?ez-Librado JL, Anaya-Mart?nez V, Gutierrez-Valdez AL, Montiel-Flores E, Corona DR, Martinez-Fong D, Avila-Costa MR (2010b) L-DOPA treatment reverses the motor alterations induced by manganese exposure as a Parkinson disease experimental model. Neurosci Lett 471: 79-82.
  40. Ordo?ez-Librado JL, Gutierrez-Valdez AL, Col?n-Barenque L, Anaya-Mart?nez V, D?az-Bech P, Avila-Costa MR (2008) Inhalation of divalent and trivalent manganese mixture induces a Parkinson\'s disease model: immunocytochemical and behavioral evidences. Neuroscience 155: 7-16.
  41. Paxinos G, Watson C (2005) The rat brain atlas in stereotaxic coordinates, Elsevier Academic Press, New York.
  42. Pilon C, Levesque D, Dimitriadou V, Griffon N, Martres MP, Schwartz JC, Sokoloff P (1994) Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol 268: 129-139.
  43. Politis M, Oertel WH, Wu K, Quinn NP, Pogarell O, Brooks DJ, Bj?rklund A, Lindvall O, et al. (2011) Graft-induced dyskinesias in Parkinson\'s disease: High striatal serotonin/dopamine transporter ratio. Mov Disor 26: 1997-2003.
  44. Porritt M, Stanic D, Finkelstein D, Batchelor P, Lockhart S, Hughes A, Kalnins R, Howells D (2005) Dopaminergic innervation of the human striatum in Parkinson\'s disease. Mov Disors 20: 810-818.
  45. Potashkin JA, Blume SR, Runkle NK (2010) Limitations of animal models of Parkinson\'s disease. Parkinsons Dis 2011: 658083.
  46. Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3-33.
  47. Rangel-Barajas C, Coronel I, Flor?n B. (2015) Dopamine Receptors and Neurodegeneration. Aging Dis 6: 349-368.
  48. Razgado-Hernandez LF, Espadas-Alvarez AJ, Reyna-Velazquez P, Sierra-Sanchez A, Anaya-Mart?nez V, Jimenez-Estrada I, Bannon MJ, Martinez-Fong D, et al. (2015) The transfection of BDNF to dopamine neurons potentiates the effect of dopamine D3 receptor agonist recovering the striatal innervation, dendritic spines and motor behavior in an aged rat model of Parkinson\'s disease PloS one, 10: e0117391.
  49. Rozas G, Lopez-Martin E, Guerra MJ, Labandeira-Garcia JL (1998) The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83: 165-175.
  50. S?nchez-Betancourt J, Anaya-Mart?nez V, Guti?rrez-Valdez AL, Ord??ez-Librado JL, Montiel-Flores E, Espinosa-Villanueva J, Reynoso-Erazo L, Avila-Costa MR (2012) Manganese mixture inhalation is a reliable Parkinson disease model in rats. Neurotoxicology 33: 1346-1355.
  51. Shin E, Lisci C, Tronci E, Fidalgo C, Stancampiano R, Bj?rklund A, Carta M (2014) The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation. Neurobiol Dis? 63: 233-240.
  52. Smith Y, Wichmann T, Factor SA, DeLong MR (2012) Parkinson\'s disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology 37:213-46.
  53. Soderstrom KE, O\'Malley JA, Levine ND, Sortwell CE, Collier TJ, Steece-Collier K (2010) Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur J Neurosci 31: 478-490.
  54. Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N (2002) Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental psychiatric disorders. Neurotox Res, 4: 671-678.
  55. Szabolcs F, Katalin N, Zhisheng J, Tibor H, Mikl?s P, Sean D, Pike VW, Halldin C, et al. (2012) The decrease of dopamine D2/D3receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1cannabinoid receptors in Parkinson?s disease: A preliminary autoradiographic study with the selective dopamine D2/D3?antagonist [3H]raclopride and the novel CB1?inverse agonist [125I]SD7015. Brain Res Bull 87: 504?510.
  56. Toy WA, Petzinger GM, Leyshon BJ, Akopian GK, Walsh JP, Hoffman MV, Vučković MG, Jakowec MW (2014) Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson\'s disease. Neurobiol Dis 63: 201-209.
  57. Valverde F (1970) The Golgi Method. A Tool for Comparative Structural Analyses, in: W.J.H. Nauta, S.O.E. Ebbesson (Eds.) Contemporary Research Methods in Neuroanatomy, Springer Berlin Heidelberg, pp. 12-31.
  58. Van Kampen JM, Eckman CB (2006) Dopamine D3 receptor agonist delivery to a model of Parkinson\'s disease restores the nigrostriatal pathway and improves locomotor behavior. J Neurosci 26: 7272-7280.
  59. Van Kampen JM, Hagg T, Robertson HA (2004) Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur J Neurosci 19: 2377-2387.
  60. Venero JL, Beck KD, Hefti F (1994) 6-Hydroxydopamine lesions reduce BDNF mRNA levels in adult rat brain substantia nigra, Neuroreport, 5: 429-432.
  61. Yao WD, Spealman RD, Zhang J (2008) Dopaminergic signaling in dendritic spines. Biochem Pharmacol 75: 2055-2069.
  62. Yurek DM, Lu W, Hipkens S, Wiegand SJ (1996) BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons. Exp Neurol 137: 105-118.
  63. Zhou J, Bradford HF, Stern GM (1994a) The response of human and rat fetal ventral mesencephalon in culture to the brain-derived neurotrophic factor treatment. Brain Res 656: 147-156.
  64. Zhou J, Bradford HF, Stern GM (1994b) The stimulatory effect of brain-derived neurotrophic factor on dopaminergic phenotype expression of embryonic rat cortical neurons in vitro. Brain Res Dev 81: 318-324.

[M. Teresa Ibarra-Gutiearrez, Veronica Anaya-Martinez, Ana L. Gutierrez-Valdez, Jose Luis Ordonez-Librado, Daniel Martinez-Fong, Jorge Aceves-Ruiz, Javier Sanchez-Betancourt, Leonardo Reynoso-Erazo, Enrique Montiel-Flores, Rocio Tron-Alvarez and *Maria Rosa Avila-Costa. (2018); CONSEQUENCES OF DOPAMINERGIC AGONIST ASSOCIATED WITH BDNF TREATMENT ON BEHAVIORAL ALTERATIONS AND CYTOLOGICAL CHANGES IN AN EXPERIMENTAL MODEL OF PARKINSON DISEASE DUE TO MANGANESE EXPOSURE. Int. J. of Adv. Res. 6 (Feb). 829-843] (ISSN 2320-5407). www.journalijar.com

Maria Rosa Avila-Costa
LABORATORIO DE NEUROMORFOLOGIA, FES IZTACALA, UNAM, AV. DE LOS BARRIOS 1, TLALNEPANTLA 54090, MEXICO.

DOI:

Article DOI: 10.21474/IJAR01/6501      
DOI URL: https://dx.doi.org/10.21474/IJAR01/6501

Download Full Paper

Download PDF No. of Downloads: 25 | No. of Views: 150